Search

Dr. Gary Deng of the Integrative Medicine Service helps separate the hype from the proven health benefits of mushroom supplements.

… Tuesday, October 22, 2024 Mushrooms have always had an aura of special power about them. People all over the world have used them as medicine in the treatment of infection, lung disease, cancer, and other conditions for thousands of years. They have long been central to traditional medicine throughout

MSK Kids, the pediatric oncology program at MSK, is committed to shining a light on pediatric cancer. While there is a significant threat to pediatric cancer research stemming from COVID-19’s impact on philanthropy, several organizations helped MSK recognize pediatric cancer awareness month by fundraising for MSK Kids.

… Friday, October 16, 2020 MSK Kids, the pediatric oncology program at MSK, is committed to shining a light on pediatric cancer. Our clinicians and care teams are engaged in groundbreaking research that will continue to create tomorrow’s breakthroughs. While there is a significant threat to pediatric cancer

By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.

… Thursday, October 28, 2021 For people with lung cancer , drug resistance is the major cause of relapse. A tumor might respond very well at first — maybe even shrinking down to an undetectable level — only to develop resistance and grow back. Scientists are learning that one of the ways that lung cancers

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.

… Friday, October 24, 2025 Immunotherapy drugs called  checkpoint inhibitors  are a promising cancer treatment, but so far only a minority of people respond to them. This has been especially notable in the treatment of  prostate cancer , the most common cancer in men, after skin cancer. Researchers at

Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.

… Tuesday, September 20, 2016 Gerstner Sloan Kettering graduate James Mahaffey works in a lab at the Perlmutter Cancer Center at NYU School of Medicine exploring the RAS gene, which is mutated in nearly a third of cancers but has resisted targeting with drugs. James Mahaffey studies RAS, a gene that is

Two of the year's top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

… Monday, February 6, 2012 Summary Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators. Two of the top five advances in cancer research for 2011 cited by the annual progress report of the American Society

Clinicians and scientists at MSK continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include, the safety and feasibility of active surveillance for certain patients, the identification of mutation profiles of subgroups, recommendations for future clinical trials of redifferentiation therapy, and study results showing that larotrectinib may be beneficial for treatment-naïve patients with NTRK fusion-positive thyroid cancer.

… Thursday, July 10, 2025 Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for patients with thyroid cancer. Recent research insights from MSK thyroid cancer experts include: the safety and feasibility of active surveillance

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering simultaneously presented today at the American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.

… Sunday, May 31, 2015 Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers

Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium.

… Monday, December 1, 2008 Summary Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium. Infection by antibiotic-resistant bacteria is a dangerous complication of broad-spectrum

Computational biologist Thomas Norman, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will receive $1.5 million in direct costs upfront in the first year of a five-year award. 

… Tuesday, October 6, 2020 Computational biologist  Thomas Norman, PhD , of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will